The 90-day, randomized, double-blind, controlled study administered a daily dose of 500 mg of PACran.
Decas Botanical Synergies (Carver, MA) announced the publication of a study in Current Bioactive Compounds examining the effects of the company’s PACran cranberry supplement on women with recurring urinary tract infections (UTIs) and a confirmed presence of E. coli in the culture of urine samples.
The 90-day, randomized, double-blind, controlled study administered a daily dose of 500 mg of PACran. The company says that at the end of the treatment period, results showed a significant reduction in the presence of E. coli and support for urinary tract health.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”